201 |
The Association Between Non-Alcoholic Fatty Liver Disease and Atrial Fibrillation: A Meta-AnalysisWijarnpreecha, Karn, Boonpheng, Boonphiphop, Thongprayoon, Charat, Jaruvongvanich, Veeravich, Ungprasert, Patompong 01 October 2017 (has links)
The association between non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF) has been suggested by recent epidemiological studies although the results were inconsistent. This meta-analysis was conducted to summarize all available data. Methods A comprehensive literature review was conducted using MEDLINE and EMBASE database through May 2017 to identify all studies that reported the risk of AF among patients with NAFLD versus those without NAFLD. Effect estimates from each study were extracted and combined together using the random-effect, generic inverse variance method of DerSimonian and Laird. Results Of 1009 studies, 5 studies (two cross-sectional studies and three cohort studies) with 238,129 participants met the eligibility criteria and were included in the meta-analysis. The risk of AF in patients with NAFLD was significantly higher than subjects without NAFLD with the pooled risks ratio of 2.06 (95% confidence interval, 1.10–3.85). The statistical heterogeneity was high with an I2 of 78%, which was the major limitation of this meta-analysis. Conclusions A significantly increased risk of AF among patients with NAFLD was demonstrated in this study.
|
202 |
An integrative and translational assessment of altered atrial electrophysiology, calcium handling and contractility in patients with atrial fibrillationFakuade, Funsho Emmanuel 22 October 2021 (has links)
No description available.
|
203 |
Thérapie génique de l'insuffisance cardiaque par les phosphodiestérases / Gene therapy of heart failure with phosphodiesterasesBourcier, Aurélia 24 October 2019 (has links)
Une stimulation β-adrénergique (β-AR) aigue, par exemple au cours d’un exercice physique, accroît le second messager AMPc dans les cardiomyocytes aboutissant à une cascade d’évènements permettant d’augmenter la fonction cardiaque. Une élévation chronique des taux de catécholamines est délétère puisqu’elle participe au remodelage pathologique du cœur et à la progression vers l’insuffisance cardiaque (IC). L'IC correspond à l'incapacité du cœur à répondre aux besoins hémodynamiques de l'organisme. Si la majorité des patients meurt de défaillance cardiaque, une part importante décède d'arythmies.Les phosphodiestérases (PDEs) sont des enzymes essentielles puisqu’elles permettent non seulement la terminaison des signaux AMPc en dégradant ce nucléotide cyclique en 5’AMP inactif mais aussi l’organisation spatiale de ces signaux dans des compartiments subcellulaires spécifiques. L'IC s'accompagne de profonds remaniements de la voie β-AR et l'expression des PDEs est modifiée en conditions pathologiques, perturbant ainsi la compartimentation intracellulaire de l’AMPc. Il a été notamment démontré que l’expression d’une isoforme de PDE particulière, la PDE4B, diminue dans l'hypertrophie cardiaque et que l’invalidation du gène codant pour celle-ci favorise les arythmies ventriculaires chez la souris lors d’une stimulation β-AR. À l’inverse, l'expression d'une autre enzyme, la PDE2A, est augmentée dans l’IC, chez l’homme et différents modèles animaux. Ceci constituerait un mécanisme de défense lors d'un stress cardiaque puisqu’il a été montré que sa surexpression atténue l’hypertrophie induite par la noradrénaline ou la phényléphrine et limite les arythmies chez la souris.L’objectif de mon travail était de tester l’hypothèse qu’une augmentation de l’activité des PDEs pourrait constituer une alternative aux traitements classiques de l’IC, pour limiter le remodelage hypertrophique, la progression vers l’IC et les arythmies associées. Pour cela, j’ai réalisé une thérapie génique dans des modèles murins d'IC grâce à des virus adéno-associé de type 9 (AAV9) codant pour la PDE4B ou la PDE2A. Mes résultats suggèrent que cette approche pourrait constituer une nouvelle stratégie thérapeutique prometteuse de l'IC en limitant le dysfonctionnement cardiaque, l’hypertrophie du ventricule gauche, et la survenue des arythmies ventriculaires mais seulement lorsque la PDE2A est surexprimée. / Acute stimulation of β-adrenergic receptors (β-ARs), for example during physical activity, leads to the synthesis of the second messenger cAMP in cardiomyocytes, which triggers a cascade of events leading to the increase of cardiac function. While acute β-AR stimulation is beneficial to the heart, chronic β-AR activation is detrimental because it promotes cardiac remodeling and ultimately leads to heart failure (HF). HF is defined by the heart's inability to overcome hemodynamic needs of the body. While the majority of patients die of worsening heart function, a significant proportion dies suddenly of cardiac arrhythmias.Phosphodiesterases (PDEs) are crucial enzymes since they allow not only to terminate cAMP signals by degrading this second messenger into inactive 5’AMP but permit their spatial organization in subcellular compartments. HF is accompanied by profound rearrangements of the β-AR pathway and the expression of PDEs is modified under pathological conditions, thus disrupting cAMP intracellular compartmentation. The expression of one of these enzymes, PDE4B, is decreased in cardiac hypertrophy and the invalidation of the gene encoding PDE4B promotes ventricular arrhythmias under β-AR stimulation in mice. Conversely, the expression of another enzyme, PDE2A, is up-regulated in human and animal models of HF which may constitute an important defense mechanism during cardiac stress since its overexpression attenuates hypertrophy induced by norepinephrine or phenylephrine and limits cardiac arrhythmias.The purpose of my work was to test the hypothesis that an increase of PDE activity could constitute an alternative to conventional HF treatments to limit cardiac remodeling, HF progression and associated arrhythmias. To do so, I performed a cardiac gene therapy in mouse models of HF using serotype 9 adeno-associated viruses (AAV9) encoding for PDE4B or PDE2A. My results suggest that this approach may be a promising new therapeutic strategy during HF by limiting cardiac dysfunction, left ventricular hypertrophy, and could protect ventricular arrhythmias only when PDE2A is overexpressed.
|
204 |
Cardiac sodium channel palmitoylation regulates channel function and cardiac excitability with implications for arrhythmia generationPei, Zifan 09 December 2016 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / The cardiac voltage-gated sodium channels (Nav1.5) play a specific and critical role in regulating cardiac electrical activity by initiating and propagating action potentials in the heart. The association between Nav1.5 dysfunctions and generation of various types of cardiac arrhythmia disease, including long-QT3 and Brugada syndrome, is well established. Many types of post-translational modifications have been shown to regulate Nav1.5 biophysical properties, including phosphorylation, glycosylation and ubiquitination. However, our understanding about how post-translational lipid modification affects sodium channel function and cellular excitability, is still lacking. The goal of this dissertation is to characterize Nav1.5 palmitoylation, one of the most common post-translational lipid modification and its role in regulating Nav1.5 function and cardiac excitability. In our studies, three lines of biochemistry evidence were shown to confirm Nav1.5 palmitoylation in both native expression background and heterologous expression system. Moreover, palmitoylation of Nav1.5 can be bidirectionally regulated using 2-Br-palmitate and palmitic acid. Our results also demonstrated that enhanced palmitoylation in both cardiomyocytes and HEK293 cells increases sodium channel availability and late sodium current activity, leading to enhanced cardiac excitability and prolonged action potential duration. In contrast, blocking palmitoylation by 2-Br-palmitiate increases closed-state channel inactivation and reduces myocyte excitability. Our computer simulation results confirmed that the observed modification in Nav1.5 gating properties by protein palmitoylation are adequate for the alterations in cardiac excitability. Mutations of potential palmitoylation sites predicted by CSS-Palm bioinformatics tool were introduced into wild-type Nav1.5 constructs using site-directed mutagenesis. Further studies revealed four cysteines (C981, C1176, C1178, C1179) as possible Nav1.5 palmitoylation sites. In particular, a mutation of one of these sites(C981) is associated with cardiac arrhythmia disease. Cysteine to phenylalanine mutation at this site largely enhances of channel closed-state inactivation and ablates sensitivity to depalmitoylation. Therefore, C981 might be the most important site that regulates Nav1.5 palmitoylation. In summary, this dissertation research identified novel post-translational modification on Nav1.5 and revealed important details behind this process. Our data provides new insights on how post-translational lipid modification alters cardiomyocyte excitability and its potential role in arrhythmogenesis.
|
205 |
The renin-angiotensin system promotes arrhythmogenic substrates and lethal arrhythmias in mice with non-ischemic cardiomyopathy / 非虚血性心筋症モデルマウスにおける不整脈源性基質形成と致死性不整脈発症へのレニン・アンジオテンシン系の関与Yamada, Chinatsu 23 March 2016 (has links)
京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第19606号 / 医博第4113号 / 新制||医||1015(附属図書館) / 32642 / 京都大学大学院医学研究科医学専攻 / (主査)教授 小池 薫, 教授 YOUSSEFIAN Shohab, 教授 川村 孝 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM
|
206 |
Modelling Torsade de Pointes arrhythmias in vitro in 3D human iPS cell-engineered heart tissue / ヒトiPS細胞による三次元心臓組織を用いたTorsade de Pointes(トルサード・ド・ポアント) 型不整脈の再現Kawatou, Masahide 26 March 2018 (has links)
京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第20978号 / 医博第4324号 / 新制||医||1026(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 井上 治久, 教授 木村 剛, 教授 瀬原 淳子 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM
|
207 |
Optical recording of action potentials in human induced pluripotent stem cell-derived cardiac single cells and monolayers generated from long QT syndrome type 1 patients / 1型QT延長症候群患者より作成したヒトiPS細胞由来心臓単細胞及び単層における光学的な活動電位記録Takaki, Tadashi 25 March 2019 (has links)
京都大学 / 0048 / 新制・論文博士 / 博士(医学) / 乙第13232号 / 論医博第2172号 / 新制||医||1036(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 山下 潤, 教授 江藤 浩之, 教授 木村 剛 / 学位規則第4条第2項該当 / Doctor of Medical Science / Kyoto University / DFAM
|
208 |
Acceptability and Familiarity of Genetic Treatment Technologies: A Survey of Individuals with Sudden Arrhythmia Death Syndrome (SADS) ConditionsMyers, Katherine Joyce 28 August 2019 (has links)
No description available.
|
209 |
Cardiac Myosin Binding Protein-C phosphorylation Regulates Calcium HomeostasisKumar, Mohit 15 October 2020 (has links)
No description available.
|
210 |
RISK FACTORS OF VENTRICULAR ARRHYTHMIA AND CARDIOVASCULAR MORTALITY IN ADULTS WITH CARDIAC SARCOIDOSISHutt, Erika 26 May 2023 (has links)
No description available.
|
Page generated in 0.0242 seconds